Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Demeester, Rémy MD*; Omes, Christine*; Karasi, Jean Claude MD†; Schneider, Serge MD‡; Mugabo, Jules MD*; Maliboli, M J MD*; Arendt, Vic MD§
*Lux Development Centre Hospitalier de Kigali, Kigali, Rwanda, †Treatment and Research AIDS Center, Kigali, Rwanda, ‡Division de Toxicologie Laboratoire National de Santé, Luxembourg, §Laboratoire de Rétrovirologie, CRP-Santé, Luxembourg.
To the Editor:
We report our experience in the Ensemble de Solidarité Thérapeutique Hospitalière En Réseau (ESTHER) antiretroviral treatment program at the Center Hospitalier de Kigali in Kigali, Rwanda. The adherence to highly active antiretroviral therapy (HAART) has been assessed in the 95 patients first started on antiretroviral therapy; group 1 (n = 27) in May 2003 (zidovudine [ZDV] and lamivudine [3TC] sold as Avocomb [Ranbaxy, Gurgaon, India] and efavirenz [EFV] sold as Stocrin [Merck, Whitehouse Station, NJ]) and group 2 (n = 68) from September to December (stavudine [d4T], 3TC, and nevirapine [NVP] in fixed-dose combinations sold as Triomune or Triviro [depending on dosage of d4T] [Cipla, Mumbai, India]). We used a standardized questionnaire and performed therapeutic drug monitoring (TDM) for the nonnucleoside component of the regimen. Eighty percent of the patients were from a low socioeconomic status, and 98% of them were at an advanced stage of the HIV infection (World Health Organization [WHO] stage III or IV). More than 90% of the patients reported adverse effects. Five percent (5 of 95 patients) admitted to having forgotten 1 to 4 doses during the last 3 days. On a visual scale, 87% (83 of 95 patients) reported no missed dose during the last month, whereas 13% (12 of 95 patients) reported having taken “most” or “nearly all” the doses. TDM for group 1 showed detectable levels of EFV in 100% of the patients: 85% (23 of 27 patients) in the therapeutic range (1-4 μg/mL) and 15% (4 of 27 patients) slightly below (0.83-0.97 μg/mL). In the second group of patients who were taking Triomune or Triviro, blood samples were obtained from 41 persons; TDM showed that 93% (38 of 41 patients) were within the therapeutic range for NVP (>3 μg/mL), whereas 5% (2 of 41 patients) had an undetectable level. We concluded that a high level of treatment adherence, confirmed by TDM, was achieved despite the poverty, the adverse effects, and the advanced clinical stage of these patients. We have noticed that counseling and family support were essential to this success. From these results as well as from those obtained by Oyugi et al,1 we conclude that adherence rates equal to those in industrialized countries may be obtained in resource-limited settings. Meanwhile the scale-up ensures that more than 150 new patients are starting antiretroviral therapy each month at the main treatment clinic, and the challenge is to maintain similar levels of adherence with large numbers of patients followed.
Rémy Demeester, MD*
Jean Claude Karasi, MD†
Serge Schneider, MD‡
Jules Mugabo, MD*
Marie Josée Maliboli*
Vic Arendt, MD§
*Lux Development Centre Hospitalier de Kigali Kigali, Rwanda †Treatment and Research AIDS Center Kigali, Rwanda ‡Division de Toxicologie Laboratoire National de Santé Luxembourg, Grand-Duché de Luxembourg §Laboratoire de Rétrovirologie CRP-Santé Luxembourg, Grand-Duché de Luxembourg
This article has been cited 4 time(s).
© 2005 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at JAIDS Journal of Acquired Immune Deficiency Syndromes.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in for
days or until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection